Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 2 1

Status

Active not recruiting 4Completed 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Lymphoid 4Other hematologic neoplasm 3

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 3Lymphoma, B-Cell, Marginal Zone 1

Interventions

pembrolizumab 374Carboplatin 276Specimen Handling 265Nivolumab 252Magnetic Resonance Spectroscopy 244Cyclophosphamide 240Cisplatin 213Paclitaxel 206Radiotherapy 195Biopsy 171Gemcitabine 155Dexamethasone 148durvalumab 143atezolizumab 126Rituximab 120Doxorubicin 115Bevacizumab 114Lenalidomide 113Ipilimumab 111Radiation 109Docetaxel 103Pemetrexed 102Etoposide 101fludarabine 97venetoclax 95Fluorouracil 92Capecitabine 92Radiosurgery 90Prednisone 89Oxaliplatin 89

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Active not recruiting × Chlorambucil × 1 year × Clear all
NCT03462719 2026-05-08

GLOW

Janssen Research & Development, LLC

Phase 3 Active not recruiting
211 enrolled 23 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT04075292 2026-03-05

Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia

AstraZeneca

Phase 3 Active not recruiting
155 enrolled 16 charts
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT01808599 2026-01-15

Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma

International Extranodal Lymphoma Study Group (IELSG)

Phase 2 Active not recruiting
112 enrolled
Lymphoid

Lymphoma, B-Cell, Marginal Zone

NCT02475681 2025-08-27

ElevateTN

Acerta Pharma BV

Phase 3 Active not recruiting
535 enrolled 19 charts 1 FDA
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡